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Purpose: For locally unresectable hepatocellular carcinoma (HCC) patients, concur-
rent chemoradiotherapy (CCRT) has been applied as a loco-regional treatment. After 
shrinkage of tumors in selected patients, surgical resection is performed. The aim of 
this study was to evaluate prognostic factors and long-term survivors in such pa-
tients. Materials and Methods: From January 2000 to January 2009, 264 patients 
with HCC were treated with CCRT (45 Gy with fractional dose of 1.8 Gy), and intra-
arterial chemotherapy was administered during radiotherapy. Eighteen of these pa-
tients (6.8%) underwent hepatic resection after showing a response to CCRT. Cases 
were considered resectable when tumor-free margins and sufficient remnant vol-
umes were obtained without extrahepatic metastasis. Prior to operation, there were 
six patients with complete remission, 11 with partial remission, and six with stable 
disease according to modified Response Evaluation Criteria in Solid Tumors. Re-
sults: In pathologic review, four patients (22.2%) showed total necrosis and seven 
patients (38.9%) showed 70‒99% necrosis. A high level of necrosis (≥80%) was cor-
related with low risk for extrahepatic metastasis and long-term survival. In univariate 
analyses, vessel invasion and capsular infiltration were significantly correlated with 
disease free survival (DFS) (p=0.017 and 0.013, respectively), and vessel invasion 
was significantly correlated with overall survival (OS) (p=0.013). In multivariate 
analyses, capsule infiltration was a significant factor for DFS (p=0.016) and vessel 
invasion was significant for OS (p=0.015). Conclusion: CCRT showed favorable re-
sponses and locally advanced HCC converted into resectable tumor after CCRT in 
selected patients. Long-term survivors showed the pathological features of near total 
necrosis, as well as negative capsule and vessel invasion.
Key Words:   Hepatocellular carcinoma, concurrent chemoradiotherapy, intra-arte-
rial chemotherapy, hepatic resection
INTRODUCTION
Hepatocellular carcinoma (HCC) is a major disease in Asian countries. Global 
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cluding metastasis, portal vein invasion, and performance 
0‒2. In this stage, National Comprehensive Cancer Network 
guidelines suggest that radiotherapy (RT) can be considered 
as an alternative to ablation/embolization techniques for un-
resectable HCC with category 2B level evidence. Lee and 
Seong4 reviewed the optimal indications for RT according to 
the BCLC staging system and the application of various RT 
modalities and prescription according to the extent of dis-
ease. Combining RT with radiosensitizers such as concurrent 
chemoradiotherapy (CCRT) is an also attractive strategy to 
increase the therapeutic ratio for these patients.5 
Several studies reported downstaging or total necrosis of 
the tumor after non-surgical modalities, including trans-
catheter arterial chemoembolization (TACE), hepatic artery 
chemo-infusion, combined systemic chemotherapy, exter-
nal radiation, and radioimmunotherapy.6-9 Although tumor 
shrinkage was sufficient to allow salvage liver resection 
following therapy in only a small proportion of patients, the 
potential for curative therapy in responders also gives hope 
to patients with unresectable HCC.
In our institute, patients with locally advanced BCLC 
stage C were treated with CCRT when surgery was not fea-
sible due to portal vein tumor thrombosis or inadequate 
non-tumor liver volume.10 Among them, some patients un-
derwent surgical resection after showing a response to 
CCRT. In this study, we evaluated prognostic factors and 
long-term survival in patients who underwent hepatic re-
section after CCRT.
MATERIALS AND METHODS
Patients
From January 2000 to January 2009, 264 patients with lo-
cally advanced HCC were treated with external beam RT 
and concurrent intra-arterial (iA) chemotherapy (CTx) when 
surgery was not feasible due to portal vein tumor thrombo-
sis or inadequate non-tumor liver volume. In some patients, 
CCRT showed a favorable response and eighteen of these 
patients (6.8%) underwent hepatic resection after multidis-
ciplinary HCC conference. All patients provided informed 
written consent for participation in this study, which was 
approved by our Institutional Review Board. Table 1 shows 
the clinical characteristics of these patients. The median fol-
low-up of the 18 patients was 40 months. 
Diagnosis of HCC was based on either pathologic confir-
mation or radiologic findings with an elevated serum α-feto-
cancer statistics showed this disease as the third most com-
mon cause of cancer-related deaths worldwide.1 Since HCC 
is unresectable in the majority of patients at the time of initial 
visiting, patients are frequently referred to non curative treat-
ments. Based on the results of randomized clinical trials, 
sorafenib has become the first-line therapy for advanced Bar-
celona Clinic Liver Cancer (BCLC) stage C HCC.2,3 Howev-
er, BCLC stage C represents a variety of disease features, in-
Table 1. Patient Characteristics
Characteristics Value (range) No. of patients (%)
Age
     Median: 51.5 
(34‒68)
Sex
    Male 17 (94.4)
    Female   1 (5.6)
Etiology
    HBV 15 (83.3)
    Non-B, -C   3 (16.7)
Child-Pugh class
    A 15 (83.3)
    B   3 (16.7)
ICG-R15 (%) Mean: 10.7 (4‒21)
Main lesion
    Rt. lobe 13 (72.2)
    Lt. lobe   5 (27.8)
Clinical stage  
  (Japanese TNM) 
    II   5 (27.8)
    III   6 (33.3)
    IV-A   7 (38.9)
Tumor size before 
  CCRT (cm)
Mean: 10.7 (5‒20)
PVT
    No 12 (66.7)
    Yes   6 (33.3)
Lymph node 
  involvement
    No 16 (88.9)
    Yes   2 (11.1)
Previous treatment
    No 12 (66.7)
    Yes   6 (33.3)
AFP, ng/mL
    ≥400   9 (50.0)
    <400   9 (50.0)
PIVKA-II, mAU/mL
    ≥200 13 (72.2)
    <200   5 (17.8)
HBV, hepatitis B virus; ICG, indocyanine green; CCRT, concurrent chemora-
diotherapy; PVT, portal vein thrombosis; AFP, α-fetoprotein; PIVKA, protein 
induced by vitamin K absence.
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were obtained.12 The resectability of tumors was finally de-
termined at multidisciplinary HCC conferences before and 
after CCRT.
Evaluation and statistical analysis
Two months after the completion of CCRT and at short-inter-
val (3‒6 months) follow-up, abdominal/pelvic CT was used 
to evaluate radiologic tumor response. Modified Response 
Evaluation Criteria in Solid Tumors criteria were used to 
evaluate responses to CCRT.13 Serum AFP and protein in-
duced by vitamin K absence (PIVKA-II) were measured at 
diagnosis and 2 months after CCRT for evaluation of chemi-
cal response, as well as at 3‒6 months during follow-up, to 
detect recurrence. For chemical response, complete remis-
sion (cCR) was defined as normalization of tumor marker, 
partial response (cPR) as at least a 50% decrease from the 
pretreatment level, progressive disease (cPD) as >25% in-
crease of tumor marker from the pretreatment level, and 
stable disease (cSD) as any changes that do not meet other 
criteria. 
A pathologist evaluated the resected tumor for evidence 
of gross and histologic necrosis after serial sectioning using 
a standard protocol (10 mm slice thickness). Slides were 
prepared using routine hematoxylin and eosin staining. The 
irradiated lesion was examined for the presence of viable 
neoplastic tissue, capsular invasion, microscopic vascular 
invasion, tumor size, tumor multiplicity, and resection mar-
gins, and a pathologist quantitatively evaluated the percent-
age of necrosis.
Patient survival was measured from the beginning of ra-
diotherapy. Overall survival (OS) and disease free survival 
(DFS) were analyzed using proportional hazards (Cox) re-
gression. The median survival time was estimated using 
Kaplan-Meier method.
RESULTS
 
Radiologic and chemical responses of CCRT
Radiologic and chemical responses were determined 2 
months after the completion of CCRT and immediately be-
fore surgical resection. Table 2 shows the results of the treat-
ment. Two months following CCRT, two (11.1%), 13 
(72.2%), and three (16.7%) patients achieved radiological 
CR, PR, and SD, respectively. Immediately before the oper-
ation, six (33.3%), 11 (61.1%), and one (5.6%) patients 
achieved CR, PR, and SD, respectively. Among the nine pa-
protein (AFP). If computed tomography (CT), magnetic 
resonance imaging (MRI), or arteriography detected a cir-
rhotic liver with a hepatic mass larger than 2 cm (which 
suggests HCC) accompanied by AFP elevated more than 
200 ng/mL, a biopsy was not necessary for HCC diagnosis. 
In order to be selected as a candidate for the CCRT proto-
col, patients needed to have an Eastern Cooperative Oncol-
ogy Group performance status of 0‒2 and adequate liver 
function [indocyanine green R15 (ICG R15) <30% and 
Child-Pugh class A or B]. Patients with tumors of diffuse or 
multifocal bilobal involvement were excluded to avoid 
whole-liver irradiation.
     
Concurrent chemoradiation
All of the 18 patients were treated with three-dimensional 
conformal radiotherapy. The gross tumor volume (GTV) 
was defined as the radiographically abnormal areas detect-
ed in the CT or MRI images, and a minimum of 5 mm 
around the GTV was added to determine the clinical target 
volume (CTV). The range of diaphragmatic movement was 
measured via fluoroscope in order to incorporate cranio-
caudal movement of the liver into defining the internal tar-
get volume (ITV). In defining planning target volume 
(PTV), an additional 5 mm for set-up error was added to 
ITV. A total of 45 Gy was prescribed to the isocenter in 25 
fractions (1.8 Gy/fraction) over 5 weeks using a 6-megavolt 
(MV) or 10-MV linear accelerator with the intention to de-
liver 95% of the prescribed dose encompassing the PTV 
around the CTV.10 
Continuous-infusion hepatic arterial 5-fluorouracil (5-
FU) at a dose of 500 mg/day was delivered during the first 
and fifth weeks of RT. One month after CCRT, hepatic arte-
rial 5-FU (at a dose of 500 mg/m2 for 5 hours on Days 1‒3) 
and cisplatin (at a dose of 60 mg/m2 for 2 hours on Day 2) 
were administered every 4 weeks for 3 to 12 cycles accord-
ing to tumor response.
Indication and criteria for salvage surgery after CCRT
To evaluate operability, all patients underwent preoperative 
liver function tests, Child-Push score reassessment, and 
measurement of the ICG R15. The extent of resection was 
determined according to the ICG R15 and gross findings of 
the liver during a laparotomy. ICG R15 <10% was regard-
ed as having no impaired liver function.11 For our hospital, 
cases were considered resectable if there was no extrahe-
patic metastasis on preoperative imaging studies, and if ad-
equate tumor-free margins and sufficient remnant volumes 
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patients at 2 months from CCRT, and cCR, cPR, or cPD 
were shown in five (28%), three (17%), and one (5.5%) pa-
tients immediately before the operation, respectively. Among 
the 13 patients with elevated PIVKA-II above 250 ng/mL, 
cCR, cPR, and cPD were observed in six (33%), five (28%), 
and two (11%) patients 2 months after CCRT. The cCR, 
cPR, and cPD were observed in seven (39%), five (28%), 
and one (5.5%) patients immediately before the operation, 
respectively.
Pathologic findings after CCRT followed by operation
The median time interval from CCRT to surgical resection 
was 6.2 months (range 1‒21 months). The numbers of pa-
tients who received right lobectomy, left lobectomy, central 
lobectomy, and bisegmentectomy were 12, four, one, and 
one, respectively. Table 3 shows reports from the patholog-
ic review. Single and multiple tumors were found in 10 
(56%) and eight (44%) patients, respectively, and four pa-
tients (22%) had tumors larger than 10 cm in diameter. Ves-
sel invasion and capsular infiltration each were confirmed 
in nine patients (50%), and close resection margin (≤1.0 
cm) was detected in seven patients (39%). Four patients 
(22%) had total necrosis, seven patients (39%) had 70‒99% 
necrosis, and less than 70% necrosis was observed in seven 
tients whose AFP level was above 200 ng/mL at diagnosis, 
cCR and cPR were achieved in two (11%) and seven (39%) 
Table 2. Treatment Results of CCRT
Response after CCRT At 2 months (%) Before OP (%)
Radiologic
    CR   2/18 (11.1)   6/18 (33.3)
    PR 13/18 (72.2) 11/18 (61.1)
    SD   3/18 (16.7)   1/18 (5.6)
AFP
    iAFP ≥200 ng/mL
        CR  2/18 (11.1)   5/18 (27.8)
        PR  7/18 (38.9)   3/18 (16.7)
        SD  0/18 (-)   0/18 (-)
        PD  0/18 (-)   1/18 (5.5)
    iAFP <200 ng/mL  9/18 (50.0)   9/18 (50.0)
PIVKA-II
    iPIVKA-II ≥250 ng/mL
        CR  6/18 (33.3)   7/18 (38.9)
        PR  5/18 (27.8)   5/18 (27.8)
        SD  2/18 (11.1)   0/18 (-)
        PD  0/18 (-)   1/18 (5.5)
    iPIVKA-II <250 ng/mL  5/18 (27.8)   5/18 (27.8)
CCRT, concurrent chemoradiation; CR, complete remission; PR, partial 
response; SD, stable disease; iAFP, α-fetoprotein at diagnosis; iPIVKA, 
protein induced by vitamin K absence at diagnosis; OP, operation; PD, pro-
gressive disease.
Table 3. Pathologic Findings after Operation
Pathologic findings No. of patients (%)
Elevated Preop AFP 
(≥200 ng/mL) 
Elevated Preop PIVKA-II 
(≥250 ng/mL)
p value (chi-square)
No. of tumors
    Single 10 (55.6)
0.87 1.00
    Multiple   8 (44.4)
Tumor size
    <10 cm 14 (77.8)
0.005 0.27
    ≥10 cm   4 (22.2)
Microscopic vascular invasion
    No   9 (50.0)
0.13 0.25
    Yes   9 (50.0)
Capsular invasion
    No   9 (50.0)
0.13 0.02
    Yes   9 (50.0)
Margin of resection ≤1.0 cm
    No 11 (61.1)
0.06 0.76
    Yes   7 (38.9)
Degree of necrosis
    <80%   7 (77.8)
0.87 0.009
    ≥80% 11 (61.1)
    <100% 14 (77.8)
0.42 0.27
    100%   4 (22.2)
No., number; AFP, α-fetoprotein; PIVKA, protein induced by vitamin K absence.
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the degree of necrosis above 80% (p=0.009).
Patterns of recurrence
The number of patients with intrahepatic metastasis was six 
(33.3%) and distant metastasis was eight (44.4%). For dis-
tant metastases, lung was the most common site, followed 
by lymph nodes, pleural/omental seeding, and the brain. In 
the analysis of patterns of treatment failure (Table 4), high 
necrosis rate (≥80%) was associated with a low incidence 
of extrahepatic metastasis (p=0.02).
patients (39%). Fig. 1 shows a case of 51-year-old male pa-
tient with a large HCC who achieved a pathologic CR (16 
cm→10 cm, 100% necrosis) following CCRT. We per-
formed a subgroup analysis to examine the correlation be-
tween pathologic findings and known biomarkers, such as 
AFP and PIVKA-II. We found that elevated levels of pre-
operative AFP (≥200 ng/mL) were a significant predictive 
factor for large tumor size (p=0.005), and elevated preoper-
ative PIVKA-II (≥250 ng/mL) levels were able to signifi-
cantly predict of the capsular invasion (p=0.02), as well as 
Fig. 1. A 51-year-old male diagnosed with 16 cm HCC in the left lobe, cT4N0M0, PVTT (+), iAFP 89.3 ng/mL; initially treated with TACE (A). 
Tumor mass slightly decreased in size, 14.6×9.1 cm, compared to pre-RTx CT images, at which it measured 16.5×10.5 cm. Focal necrosis 
and radiation induced changes are shown (B). Partial response shown in C (preop image 10×9 cm, preop AFP 2.0 ng/mL). Concurrent 
chemoradiotherapy (CCRT) 45 Gy with intra-arterial chemotherapy (iA CTx), followed by iA CTx 6 cycles (D). Left lobectomy 15 months af-
ter CCRT, 100% necrosis, negative resection margin, vascular invasion, and capsule invasion (E). He remained disease free, until now, 69 
months after surgical resection. HCC, hepatocellular carcinoma; iAFP, α-fetoprotein at diagnosis; TACE, transcatheter arterial chemoem-
bolization; PVTT, portal vein tumor thrombosis; RTx, radiotherapy. 
A
D
B C
E
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crosis, and two PRs with 90‒100% necrosis were achieved, 
and neither vascular nor capsular invasion was detected in 
pathologic findings.
DISCUSSION
Surgical resection of tumors gives the best opportunity of a 
cure for patients with HCC. However, the resectability of 
HCC is low at initial diagnosis (10‒30%). Among the un-
rectable patients, patients with poor general condition or 
decompensated liver disease could be candidates for tumor 
downstaging and salvage liver resection. The decision mak-
ing for the unresectability of HCC include a large tumor 
volume with insufficient normal hepatic mass after liver re-
section, extensive and multifocal bilobar tumors, extrahe-
patic spread of the disease, and tumors with main portal 
vein/hepatic vein/inferior vena cava tumor thrombus. For 
Asian patients, 80‒90% of cases of HCC develop in cir-
rhotic livers. Although a normal liver can permit up to 80% 
of resection of functional liver volume, cirrhotic liver is a 
major risk factor for the development of postoperative liver 
insufficiency, failure, and mortality. Even minor resection 
of a cirrhotic liver can result in post-resection liver failure. 
Therefore, the resection of liver that should be safely moni-
tored according to the degree of cirrhosis, the functional re-
serve, and the regenerative response to the surgical inter-
vention. A main vessels tumor thrombus usually occurs as a 
late complication of large or diffuse HCC, and is associated 
with a poor median survival of 2 months. Such tumors are 
therefore traditionally considered unsuitable for partial hep-
atectomy. However, the decision on whether or not a tumor 
is resectable is still largely subjective. This is a common 
criticism of studies on salvage surgery following tumor 
downstaging. In radiation oncologists’ view, “locally ad-
vanced hepatocellular carcinoma” is defined as disease not 
acceptable to surgical resection or immediate liver trans-
plantation. The extent of disease could be defined by BCLC 
Survival analysis and prognostic factors
The 3-year OS and DFS were 59.3% and 33.3%, respective-
ly, and the median OS and DFS were 61.8 months and 24.1 
months, respectively. In univariate analyses, vessel invasion 
was significant for decreased OS (p=0.013), while other 
variables including capsule invasion, positive resection mar-
gin, necrosis less than 100%, and tumor size ≥10 cm showed 
no significant correlation with OS. Findings of vessel inva-
sion and capsular infiltration were significant for decreased 
DFS (p=0.017 and 0.013). In multivariate analyses, vessel 
invasion was a significant factor for OS (p=0.015), and cap-
sule infiltration was significantly correlated with DFS (p= 
0.016) (Table 5).
Patients who had no evidence of disease for long-term 
(>5 years)
Table 6 shows clinical and pathologic factors of the three pa-
tients who had no evidence of disease for long-term (>5 
years) at the time of surgical treatment. The stage of these pa-
tients was III or VI-A, and the range of tumor size was 7‒16 
cm. Because two of them had portal vein thrombosis and an-
other had extensive multi-lobar tumors, although the tumor 
size was not huge (7 cm), they did not undergo surgery as the 
first treatment. After CCRT, these patients showed good re-
sponse (CR or PR) and the disease was converted to opera-
ble stage. Before surgical treatment, preoperative levels of 
tumor markers (AFP and PIVKA-II) were normalized in all 
patients. After operation, one radiologic CR with 100% ne-
Table 4. Pathologic Variables and Patterns of Intra/Extrahe-
patic Metastases 
Pathologic factors
Intrahepatic mets Extrahepatic mets
p value (chi-square)
Tumor size ≥10 cm 0.109 0.163
Necrosis  100% 0.423 0.043
Necrosis ≥80% 0.094 0.020
Resection margin (+) 0.737 0.914
Vessel invasion (+) 0.317 0.058
Capsule invasion (+) 0.317 0.058
Table 5. Univariate and Multivariate Analysis for Overall and Disease Free Survival 
Variables
Univariate analysis Multivariate analysis
OS DFS OS DFS
Vessel invasion 0.013 0.017 0.015 0.275
Capsule invasion 0.163 0.013 0.908 0.016
Resection margin 0.299 0.594 0.234 0.510
Necrosis 100% 0.215 0.276 0.713 0.583
Tumor size ≥10 cm 0.120 0.764 0.292 0.524
OS, overall survival; DFS, disease free survival.
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highly selected patients.
Tang, et al.6 reported residual disease in 69.7% of the sur-
gical specimens resected after combination treatments. Ma-
jno, et al.7 described that downstaging or total necrosis of 
the tumor after TACE occurred in 62% of liver resected pa-
tients. A total necrosis after TACE was reported at 24 pa-
tients (50%). In liver transplantation cases, downstaging of 
tumors >3 cm (54% of patients) and total necrosis (28% of 
patients) were associated with superior disease-free surviv-
al (p=0.01 and p=0.03). Huang, et al.8 also mentioned that 
only a small portion of tumors showed complete necrosis 
after TACE. Total necrosis (100%) of tumor was observed 
in 11.1% of 117 patients. Fan, et al.9 showed that complete 
tumor necrosis occurred in 11 patients (16.9%). There were 
6 patients who had undergone five TACE treatments each, 
but their percentage of necrotic area was only 60‒90%. 
Choi, et al.12 reported six patients (12%) who had under-
gone TACE followed by RT showed total necrosis. 
Since the waiting list is long and patients may drop out 
owing to tumor progression, radiation therapy may have a 
role in selected patients. There are several studies on using 
radiation therapy as a bridge to liver transplant. Sandroussi, 
et al.27 reported their experience with treating 10 patients 
with conformal radiotherapy as a novel bridge to liver trans-
plantation. There was no complete tumor necrosis and 4 pa-
tients demonstrated a pathological response with the degree 
of necrosis ranging from 40% to 90%. The lack of complete 
necrosis may be related to the sublethal radiation dose, ow-
ing to concerns about radiation-induced liver disease. In a 
recent case report, the explant demonstrated complete his-
tological necrosis of the lesion after external-beam radiother-
apy in patients who were candidates for liver transplantation.28 
O’Connor, et al.29 also reported that the explant pathology re-
vealed no viable tumor in three of the 11 tumors they studied, 
resulting in a complete response rate of 27%. Our pathologi-
cal review of resected specimens after CCRT showed a simi-
lar rate of complete necrosis (22.2%), and 7 patients (38.9%) 
showed 70‒99% necrosis. For the patterns of failure, the 
number of patients with intrahepatic metastases was six 
(33.3%), and high necrosis (≥80%) indicated a low risk for 
extrahepatic metastasis. These results demonstrate that us-
ing radiation therapy as a bridge to liver transplant provided 
a clear advantage in terms of local tumor control. In several 
studies, vascular invasion, multiple tumors, a high value of 
AFP, and cirrhosis were shown to be significant prognostic 
factors for survival after resection of huge HCC.30-32 Tumor 
size is also an important predictor for disease free survival 
(B) intermediate stage or BCLC (C) advanced stage with-
out extrahepatic spread except for regional lymph node in-
volvement.14 In our study, the resectability of tumors was 
determined at multidisciplinary HCC conferences before 
and after CCRT. 
Recent reports have revealed that RT can be delivered at a 
high dose to the focal liver with acceptable complications.15-18 
Global experience with the use of a combination of RT and 
radiosensitizers in HCC treatment is limited.5 CCRT has 
shown excellent tumor responses with prolonged survival in 
selected series of HCC patients.19-21 However, there is a still 
risk of radiation induced toxicity. We previously reported that 
several factors, such as tumor size, pre-RT ICG-R15, and 
Child-Pugh class could be useful for predicting radiation 
hepatotoxicity in HCC patients treated with RT.22-24 Han, et 
al.10 reported the therapeutic effect of concurrent fluorouracil 
(5-FU) and RT followed by iA CTx in patients with locally 
advanced HCC with portal vein thrombosis. In most tumor 
sites, the majority of experience with radiation sensitizers is 
through systemically delivered agents. In HCC, however, 
there has been more experience with hepatic arterial regional 
chemotherapy delivered with RT.25,26 The rationale for se-
lective radiosensitization is that the exposure of non-tumor 
normal tissues to radiosensitizer is reduced, improving the 
therapeutic ratio and potentially leading to increased doses to 
the focal HCC, thereby increasing the tumor response. Re-
gional perfusion of drugs with high hepatic extraction rates 
and short serum half-lives allow much higher drug doses to 
be delivered to focal HCCs. iA CTx alone or with TACE, 
takes advantage of this selective blood supply to HCC versus 
normal liver. In our study, all patients had Child Pugh A liver 
function. The objective response rate was 45% (18 of 40 pa-
tients). The actuarial 3-year OS rate was 24.1%, and the me-
dian survival time was 13.1 months from the start of RT. The 
results were better than a similar group of patients with a 
4‒6 months median survival.10 Following this treatment, 
the shrunken tumor as well as compensatory hyperplasia of 
the non-tumor liver allowed for surgical resection in a small 
portion of patients. According to the initial response after lo-
calized CCRT, patients with good response showed signifi-
cantly improved survival (p=0.033). The median survival 
time of responders was 19.9 months, compared with 11.4 
months for non-responders. In our study, 264 patients with 
HCC were treated with CCRT, and 18 patients (6.8%) un-
derwent hepatic resection. These patients showed better 
3-year OS (59.3%) than our previous results of our CCRT 
study (24.1%). However, this result was restricted from 
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CCRT showed favorable response and locally advanced 
HCC converted into resectable tumor after CCRT. Long-
term survivors showed the pathological features of near total 
necrosis, as well as negative capsule and vessel invasion. 
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